Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanisms in failure of infliximab for Crohn's disease.
Nikolaus S, Raedler A, Kühbacker T, Sfikas N, Fölsch UR, Schreiber S. Nikolaus S, et al. Among authors: sfikas n. Lancet. 2000 Oct 28;356(9240):1475-9. doi: 10.1016/s0140-6736(00)02871-3. Lancet. 2000. PMID: 11081530 Clinical Trial.
Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis.
Mallucci G, Zimmer A, Sfikas N, Cerdá-Fuertes N, Wunderlin S, Athanasopoulou I, Mroczek M, Phavanh V, Sanak L, Suter J, Friedli B, Kel J, Trouillet T, Simmen S, Ocampo A, Wei W, Kieseier B, Kamm CP, Kappos L, D'Souza M. Mallucci G, et al. Among authors: sfikas n. Mult Scler. 2024 Dec 20:13524585241305966. doi: 10.1177/13524585241305966. Online ahead of print. Mult Scler. 2024. PMID: 39704409
Opportunities and challenges with decentralized trials in Neuroscience.
Burger HU, Van de Casteele T, Rantell KR, Corey-Lisle P, Sfikas N, Abt M; Working group on Decentralized Trials as part of the European Scientific Interest Group (ESIG) in Neuroscience. Burger HU, et al. Among authors: sfikas n. Biom J. 2023 Dec;65(8):e2200370. doi: 10.1002/bimj.202200370. Epub 2023 Aug 23. Biom J. 2023. PMID: 37609878
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J; TRANSFORMS study group. Barkhof F, et al. Among authors: sfikas n. Mult Scler. 2014 Nov;20(13):1704-13. doi: 10.1177/1352458514532317. Epub 2014 May 8. Mult Scler. 2014. PMID: 24812043 Clinical Trial.
18 results